Werewolf Therapeutics' Full Moon Moment

10/08/2025

Werewolf Therapeutics is excited to announce the U.S. FDA has granted Fast Track Designation to WTX-124 for the potential treatment of patients with locally advanced or metastatic cutaneous after standard of care immunotherapy.

This milestone reflects our unwavering commitment to patients who face limited treatment options. We look forward to working closely with the FDA to advance this therapy and deliver meaningful progress.

Read more: https://investors.werewolftx.com/news-releases/news-release-details/werewolf-therapeutics-receives-fast-track-designation-us-fda-wtx

08/25/2025

Now enrolling patients with cutaneous melanoma, cutaneous squamous cell carcinoma, renal cell carcinoma, or non-small cell lung cancer into the WTX-124 Phase 1/1b clinical trial.

Find eligibility requirements at werewolftx.com/clinical-trials and follow our page for more updates.

This is a Phase 1/1b, open-label, multicenter, dose-escalation, and dose-expansion clinical trial designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of WTX-124, a conditionally activated IL-2 INDUKINE™ molecule, in adults with selected advanced or metastatic solid t...

08/25/2025

We’re howling with excitement! Fierce Pharma Marketing featured our “Full Moon Moment” campaign, illuminating emerging results from clinical trials of our powerful, tumor-targeted cytokine treatments.

What’s a Full Moon Moment? It’s that powerful turning point, when an investigational treatment shows confirmed results and lives begin to change. These moments fuel our mission and reflect the potential of our conditionally activated cytokine therapies WTX‑124 and WTX‑330.

Delve into the full article here: https://www.fiercepharma.com/marketing/werewolf-therapeutics-celebrates-full-moon-moments-clinical-trial-recruitment-push

To learn more about our trials and your potential Full Moon Moment, email us at [email protected]

Werewolf Therapeutics is transforming its brand awareness and clinical trial recruitment efforts with a new campaign. | Werewolf Therapeutics is transforming its brand awareness and clinical trial recruitment efforts with a new campaign.

08/13/2025

We are inspired by the incredible response one patient has made in the WTX-124 trial, bringing new hope for people facing immunotherapy-refractory squamous cell carcinoma.

At Werewolf Therapeutics, we call this a Full Moon Moment—when our treatment “wakes up” right inside the tumor to help the immune system fight back.

If you or a loved one is facing advanced cancer, our clinical trials are open at locations across the country:
📍 1 – HonorHealth Research Institute, AZ
📍 2 – Moffitt Cancer Center, FL
📍 3 – Emory Winship Cancer Institute, GA
📍 4 – Northwestern University, IL
📍 5 – Indiana University Melvin and Bren Simon Comprehensive Cancer Center, IN
📍 6 – Hackensack University Medical Center, NJ
📍 7 – Roswell Park Comprehensive Cancer Care, NY
📍 8 – Providence Cancer Institute Franz Clinic, OR
📍 9 – University of Texas Southwestern Medical Center, TX
📍 10 – Texas Oncology - Austin Midtown, TX
📍 11 – NEXT Oncology, TX (2 locations)
📍 12 – Minnesota Oncology Hematology, MN

Enrollment is open. For further study details on eligibility and contact information for participating sites, please email [email protected] or visit https://werewolftx.com/clinical-trials/

08/13/2025

Thinking about a clinical trial but not sure if it’s right for you?

At Werewolf Therapeutics, we call it the Full Moon Moment, that special point when a treatment “wakes up” and starts working exactly where it’s needed.

Joining a clinical trial means you could be part of that moment, helping your body fight cancer in a new, targeted way.

We’re here to support you with clear answers and respect for your journey, every step of the way.

Want to learn if a study might be right for you? Reach out anytime. Your Full Moon Moment could be just ahead.

📩 [email protected]
🔍 werewolftx.com/clinical-trials

08/12/2025

📣 Now Enrolling: Clinical Trial for Advanced Solid Tumors and Lymphoma

At Werewolf Therapeutics, we call it the Full Moon Moment, that point when our science “wakes up” right where it’s needed.

We are currently enrolling patients for a clinical trial evaluating WTX-330 (Clinical Trials ID: NCT06939283). This investigational treatment is designed to activate the immune system inside the tumor, helping the body launch a strong and targeted attack against cancer.

The trial is enrolling patients with specific cancers who have progressed on other standard therapies. The trial arms are focused on patients with:
✔️ Metastatic cutaneous melanoma that has shown resistance to other checkpoint inhibitor immunotherapies
✔️Metastatic colorectal cancer (specifically microsatellite-stable or MSS) that is immunotherapy-naïve
✔️Advanced non-Hodgkin lymphoma, including follicular lymphoma or diffuse large B-cell lymphoma, who have relapsed or have disease that is resistant to at least two prior therapies

If you or someone you know is facing one of these cancers and looking for new treatment options, we’re here to help you explore whether you're eligible for this study. To learn more about your potential Full Moon Moment, email us at [email protected] or visit werewolftx.com/clinical-trials

08/12/2025

📣 Now Enrolling: Clinical Trial for Advanced or Metastatic Solid Tumors

Every treatment needs the right moment to shine. At Werewolf Therapeutics, we call that the Full Moon Moment, when our investigational therapies activate only where they’re needed, right at the tumor.

We are currently enrolling patients for a clinical trial evaluating WTX-124 (Clinical Trials ID: NCT05479812), an investigational treatment designed to stimulate cancer-fighting immune cells directly inside the tumor, leaving healthy tissue untouched.

This study is focused on individuals with specific skin cancer and other malignancies where immunotherapy is a critical part of the treatment, including:
✔️ Cutaneous melanoma
✔️ Cutaneous squamous cell carcinoma
✔️ Renal cell carcinoma
✔️ Non-small cell lung cancer

If you or someone you know is facing one of these cancers and looking for new treatment options, we’re here to help you explore whether you're eligible for this study. To learn more about your potential Full Moon Moment, email us at [email protected] or visit werewolftx.com/clinical-trials

08/11/2025

What does a werewolf have to do with fighting cancer? More than you might think.

At Werewolf Therapeutics, our name reflects how our science works. Just like a werewolf stays hidden until the right time, our investigational therapies are designed to remain inactive in the body until they reach the tumor, where they "wake up" and trigger a targeted immune response to help the body attack cancer cells right where it matters most — your very own Full Moon Moment. This approach has the potential to be more effective while minimizing side effects, and it's being tested right now in two clinical trials:

🧬 WTX-124 for cutaneous melanoma, cutaneous squamous cell carcinoma, renal cell carcinoma, and non-small cell lung cancer
🧬 WTX-330 for metastatic cutaneous melanoma resistant to checkpoint inhibitors, microsatellite-stable colorectal cancer, and relapsed/refractory non-hodgkin lymphoma

Curious if you may be eligible for one of our clinical trials? Email us at [email protected] to learn more, or explore study details at werewolftx.com/clinical-trials

08/08/2025

Werewolf Therapeutics’ clinical trials are underway, and they’re already changing lives.

Werewolf is exploring a new kind of targeted immunotherapy for people living with cancer, specifically those with solid tumors. The clinical trials focus on treatments designed to activate only at the tumor site, with the goal of minimizing side effects often associated with other treatments.

And it's already showing promise.

In the WTX-124 trial, one patient with advanced cutaneous squamous cell carcinoma has been in remission for over a year. That’s one full orbit around the sun, cancer-free. Read their story: https://investors.werewolftx.com/news-releases/news-release-details/honorhealth-research-institute-patient-advanced-skin-cancer

Enrollment is open and the next step could start today. For further study details on eligibility and contact information for participating sites, please email [email protected] or visit https://werewolftx.com/clinical-trials/